The Food & Drug Administration classified the recall of approximately 17,000 CareFusion Corp. (NYSE:CFN) Alaris PC infusion units as a Class I recall.
That’s the most serious level of product recalls for the federal watchdog agency, indicating a reasonable probability that the use of the recalled product "will cause serious adverse health consequences or death," according to the FDA.